Cancer Gene Therapy (Prostate)

AD Vector Expressing WTp53 Inhibits Prostate Cancer Cell Proliferation

Published in Gene Therapy Weekly, February 5th, 1996

A recombinant adenoviral vector which expresses wild-type p53 inhibits prostate cancer cell proliferation in vitro.

Gene therapy strategies for human prostate cancer include: ex vivo manipulation of prostate cancer cells to produce recombinant cytokines; cancer cell vaccines; and correction of known molecular defects in cancer cells. All of these processes involve manipulation of autologous cells from the patient, and can be expensive, time consuming protocols.

It would be anticipated, and has been shown, that cancer cells that have mutant or no endogenous p53 could exhibit growth inhibition if normal p53 function was restored....

Want to see the full article?

Purchase this article for only $3.00

We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.

Welcome to NewsRx!

Learn more about a six-week, no-risk free trial of Gene Therapy Weekly

Source: Gene Therapy Weekly (1996-02-05)

NewsRx is Social

Top Medical Newsletters

Awards

Best Health/Healthcare Content, 2012
Best Health/Healthcare Content, 2011
Best e-Business Site, 2010
Best e-Business Site, 2009
Best e-Business Site, 2008
Best e-Business Site, 2007
Best e-Business Site, 2006
Best Healthcare Content, 2005
Best Overall Internet Site, 2005
Best Interactive Site, 2005

Facts & Stats

NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.

Google 2010 PageRank: #2 Among Top Health News and Media Publications
Google 2010 PageRank: #2 Among Top Science Publications in Biology/Physiology
Google 2010 PageRank: #2 Among Top News and Media for the Business of Pharmaceuticals
Amazon's Alexa 2010 PageRank: #2 News and Media Site for the Pharmaceutical Industry